Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Int J Cardiol ; 155(3): 430-6, 2012 Mar 22.
Article in English | MEDLINE | ID: mdl-21696837

ABSTRACT

BACKGROUND: Asperosaponin X was isolated from the roots of Dipsacus asper. In this study, we investigated the anti-myocardial ischemia and reperfusion (I/R) injury effects of Asperosaponin X in vivo and elucidated the potential mechanism in vitro. RESULTS: Asperosaponin X significantly attenuated hypoxia-induced cytotoxicity in a concentration-dependent manner in H9c2 cells. Treatment of H9c2 cells with Asperosaponin X 5 µM or 10 µM blocked TNF-α-induced nuclear factor kappaB (NF-κB) phosphorylation by blocking HMGB1 expression. Treatment of rats with Asperosaponin X 10mg/kg, (i.v.) protected the animals from myocardial I/R injury as indicated by a decrease in infarct volume, improvement in hemodynamics and reduction of myocardial damage severity. Treatment with Asperosaponin X also lowered serum levels of pro-inflammatory factors and reduced High mobility group box-1 protein (HMGB1), phosphorylated IκB-α and NF-κB expression in ischemic myocardial tissue. Additionally, continuous i.v. of Asperosaponin X 14 days attenuated cardiac remodeling. CONCLUSIONS: These protective effects suggested that Asperosaponin X may be due to block of myocardial inflammatory cascades through an HMGB1-dependent NF-κB signaling pathway.


Subject(s)
Dipsacaceae , Myocardial Reperfusion Injury/prevention & control , Plant Preparations/therapeutic use , Animals , Blotting, Western , Cells, Cultured , Disease Models, Animal , HMGB1 Protein/biosynthesis , I-kappa B Proteins/biosynthesis , Male , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/physiopathology , Myocardium/metabolism , Myocardium/pathology , NF-KappaB Inhibitor alpha , NF-kappa B/antagonists & inhibitors , Rats , Rats, Sprague-Dawley
2.
Phytomedicine ; 19(3-4): 217-22, 2012 Feb 15.
Article in English | MEDLINE | ID: mdl-21978885

ABSTRACT

Connective tissue growth factor (CTGF) plays a pathogenic role in diabetic nephropathy (DN). Loganin, an iridoid glucoside compound was isolated from Cornus officinalis Sieb. et Zucc. This study was conducted to investigate the efficacy of loganin on DN and to elucidate the potential mechanism. High glucose (HG) stimulated cultured human renal proximal tubular epithelial cells (HK-2) analyzed CTGF expression by Western blotting and investigated whether extracellular signal-regulated kinase (ERK) signaling pathway was involved. Streptozotocin (STZ)-induced experimental DN, randomized to receive intragastric (i.g.) of loganin. Renal tissue, blood and urine samples were collected to determine and analyze. In vitro study, loganin reduced CTGF excretion in HG-induced HK-2 cells through the ERK signaling pathway. In vivo study, I.g. of loganin 5 mg/kg or 10 mg/kg significantly ameliorated renal function and increased body weight. Meanwhile, loganin reduced renal CTGF expression by immunohistochemical staining, reduced serum levels of CTGF. Besides, there were no significant differences in blood sugar levels between the loganin groups compared to the STZ-treated group. Furthermore, loganin ameliorated renal pathology. These results suggested that loganin exerts an early renal protective role to DN. Inhibition of CTGF may be a potential target in DN therapy, which highlights the possibility of using loganin to treat DN.


Subject(s)
Connective Tissue Growth Factor/analysis , Diabetic Nephropathies/chemically induced , Diabetic Nephropathies/drug therapy , Iridoids/pharmacology , Animals , Blood Glucose/chemistry , Cell Line , Cell Proliferation , Connective Tissue Growth Factor/blood , Connective Tissue Growth Factor/urine , Cornus/chemistry , Cystatin C/chemistry , Diabetes Mellitus, Experimental/physiopathology , Diabetic Nephropathies/pathology , Epithelial Cells/drug effects , Glucose/pharmacology , Humans , Immunohistochemistry , Iridoids/administration & dosage , Iridoids/chemistry , Kidney/drug effects , Kidney/pathology , MAP Kinase Signaling System , Male , Rats , Rats, Sprague-Dawley , Weight Gain
3.
Phytother Res ; 26(7): 981-7, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22147417

ABSTRACT

The present study investigated the effects of Forsythoside B on an experimental model of sepsis induced by caecal ligation and puncture (CLP) in rats and elucidated the potential mechanism in cultured RAW 264.7 cells. Results showed that Forsythoside B concentration-dependently down-regulated the levels of TNF-α, IL-6 and high-mobility group-box 1 protein (HMGB1) in lipopolysaccharide (LPS)-stimulated RAW264.7 cells, inhibited the IκB kinase (IKK) pathway and modulated nuclear factor (NF)- κB. Intravenous injection (i.v.) of Forsythoside B alone or plus Imipenem reduced serum levels of TNF-α, IL-6, HMGB1, triggering receptor expressed on myeloid cells (TREM-1) and endotoxin, while the serum level of IL-10 was up-regulated and myeloperoxidase (MPO) in lung, liver and small intestine was reduced. Meanwhile, i.v. of Forsythoside B alone or plus Imipenem reduced CLP-induced lethality in rats. These data indicated that the antisepsis effect of Forsythoside B is mediated by decreasing local and systemic levels of a wide spectrum of inflammatory mediators. Its antisepsis mechanism may be that Forsythoside B binds to LPS and reduces the biological activity of serum LPS, and inhibits NF-κB activition. Our studies enhance the case for the use of Forsythoside B in sepsis. Forsythoside B itself has promise as a therapy for the treatment of sepsis in humans.


Subject(s)
Caffeic Acids/pharmacology , Glucosides/pharmacology , Inflammation Mediators/metabolism , Sepsis/drug therapy , Animals , Cell Line , HMGB1 Protein/metabolism , I-kappa B Kinase/metabolism , Imipenem/pharmacology , Interleukin-10/blood , Interleukin-6/metabolism , Intestine, Small/drug effects , Lipopolysaccharides/pharmacology , Liver/drug effects , Lung/drug effects , Male , Mice , NF-kappa B/metabolism , Peroxidase/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Immunologic/metabolism , Triggering Receptor Expressed on Myeloid Cells-1 , Tumor Necrosis Factor-alpha/metabolism
4.
Phytomedicine ; 18(4): 266-71, 2011 Feb 15.
Article in English | MEDLINE | ID: mdl-20739159

ABSTRACT

Cornuside is a secoiridoid glucoside isolated from the fruit of Cornus officinalis SIEB. et ZUCC. In this study, we investigated the anti-myocardial ischemia and reperfusion (I/R) injury effects of cornuside in vivo and elucidated the potential mechanism. Rat models of myocardial I/R were induced by coronary occlusion followed by reperfusion or by Isoproterenol (ISO), treatment of rats with cornuside (20 and 40 mg/kg, i.v.) protected the animals from myocardial I/R injury as indicated by a decrease in infarct volume, improvement in hemodynamics and reduction of myocardial damage severity. Treatment with cornuside also attenuated polymorphonuclear leukocytes (PMNs) infiltration, decreased myeloperoxidase (MPO) activity in the heart, lowered serum levels of pro-inflammatory factors and reduced phosphorylated IκB-α and nuclear factor kappa B (NF-κB) levels in the heart. Additionally, cornuside was shown to have remarkable antioxidant activity and inhibited ISO-induced myocardial cell necrosis. Thus, cornuside appeared to protect the rat from myocardial I/R injury by acting as an anti-inflammatory agent. These findings suggested that cornuside may be used therapeutically in the setting of myocardial I/R where inflammation and oxidant injury are prominent.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Cornus/chemistry , Glucosides/therapeutic use , Myocardial Infarction/prevention & control , Myocardial Reperfusion Injury/drug therapy , Phytotherapy , Pyrans/therapeutic use , Animals , Anti-Inflammatory Agents/pharmacology , Antioxidants/metabolism , Antioxidants/pharmacology , Antioxidants/therapeutic use , Disease Models, Animal , Drugs, Chinese Herbal/pharmacology , Drugs, Chinese Herbal/therapeutic use , Glucosides/chemistry , Glucosides/pharmacology , Heart/drug effects , Hemodynamics/drug effects , Inflammation/metabolism , Inflammation/prevention & control , Male , Myocardial Infarction/metabolism , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/pathology , Myocardium/metabolism , Myocardium/pathology , Plants, Medicinal/chemistry , Pyrans/chemistry , Pyrans/pharmacology , Rats , Rats, Sprague-Dawley
5.
Phytother Res ; 24(4): 547-52, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20041427

ABSTRACT

This study was conducted to investigate the efficacy of cornin, an iridoid glycoside, in an experimental cerebral ischemia induced by middle cerebral artery occlusion (MCAO) and reperfusion (I/R), and to elucidate the potential mechanism. Adult male Sprague-Dawley rats were subjected to MCAO for 1 h, then reperfusion for 23 h. Behavioral tests were used to evaluate the damage to central nervous system. The cerebral infarct volume and histopathological damage were assessed to evaluate the brain pathophysiological changes. Spectrophotometric assay methods were used to determine the activities of superoxide dismutase (SOD) and glutathione-peroxidase (GPx). Contents of malondialdehyde (MDA), the generation of reactive oxygen species (ROS) as well as respiratory control ratio and respiratory enzymes of the brain mitochondria were also determined. The results showed that cornin significantly decreased neurological deficit scores, and reduced cerebral infarct volume and degenerative neurons. Meanwhile, cornin significantly increased the brain ATP content, improved mitochondrial energy metabolism, inhibited the elevation of MDA content and ROS generation, and attenuated the decrease of SOD and GPx activities in brain mitochondria. These findings indicate that cornin has protective potential against cerebral ischemia injury and its protective effects may be due to amelioration of cerebral mitochondrial function and its antioxidant property.


Subject(s)
Infarction, Middle Cerebral Artery/drug therapy , Iridoids/therapeutic use , Phytotherapy , Verbena , Animals , Brain/metabolism , Brain/pathology , Calcium/metabolism , Cell Respiration/drug effects , Electron Transport/drug effects , Glutathione Peroxidase/metabolism , Infarction, Middle Cerebral Artery/metabolism , Infarction, Middle Cerebral Artery/pathology , Iridoid Glycosides , Male , Malondialdehyde/metabolism , Membrane Fluidity/drug effects , Mitochondria/drug effects , Mitochondria/metabolism , Mitochondrial Membranes/metabolism , Neuroprotective Agents/therapeutic use , Phospholipids/metabolism , Plant Extracts/therapeutic use , Rats , Rats, Sprague-Dawley , Reactive Oxygen Species/metabolism , Reperfusion Injury/drug therapy , Superoxide Dismutase/metabolism , Water/metabolism
6.
Phytomedicine ; 17(3-4): 282-8, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19524418

ABSTRACT

This study was carried out to investigate whether rosmarinic acid (RA) has antifibrotic effect on experimental liver fibrosis in vitro and in vivo and its possible mechanism. Culture of hepatic stellate cells (HSCs) determine proliferation and expression of transforming growth factor-beta1 (TGF-beta1), connective transforming growth factor (CTGF) and alpha-smooth muscle actin (alpha-SMA). In carbon tetrachloride (CCL(4))-induced rat liver fibrosis model, determined biochemical indicator, liver fibrosis grade and histopathological changes, immunohistochemical detected liver TGF-beta1 and CTGF expression. The results indicated that RA could inhibit HSCs proliferation, inhibit TGF-beta1, CTGF and alpha-SMA expression in cultured HSCs. It has marked evident in reducing fibrosis grade, ameliorating biochemical indicator and histopathological morphology, reducing liver TGF-beta1 and CTGF expression in CCL(4)-induced liver fibrosis. These findings suggest that RA has potentially conferring antifibrogenic effects.


Subject(s)
Antioxidants/therapeutic use , Carbon Tetrachloride Poisoning/drug therapy , Cinnamates/therapeutic use , Depsides/therapeutic use , Hepatic Stellate Cells/drug effects , Liver Cirrhosis/drug therapy , Liver/drug effects , Plant Extracts/therapeutic use , Actins/metabolism , Animals , Antioxidants/pharmacology , Carbon Tetrachloride Poisoning/complications , Cell Proliferation/drug effects , Cells, Cultured , Cinnamates/pharmacology , Connective Tissue Growth Factor/antagonists & inhibitors , Depsides/pharmacology , Disease Models, Animal , Liver/metabolism , Liver/pathology , Liver Cirrhosis/etiology , Liver Cirrhosis/metabolism , Male , Phytotherapy , Plant Extracts/pharmacology , Rats , Rats, Sprague-Dawley , Transforming Growth Factor beta1/antagonists & inhibitors , Rosmarinic Acid
7.
Planta Med ; 75(14): 1470-5, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19644810

ABSTRACT

Astilbin, a flavonoid compound, was isolated from the rhizome of Smilax glabra Roxb. This study was conducted to investigate the efficacy of astilbin on experimental diabetic nephropathy (DN) in vivo and in vitro and its possible mechanisms. Astilbin was added in high glucose stimulated HK-2 cells, streptozotocin-induced experimental DN, randomized to receive intragastric ( I. G.) astilbin to observe its anti-renal lesion effect. Results showed that astilbin inhibited high glucose stimulated HK-2 cell production of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) in vitro, especially CTGF; analogic results was also found in vivo. I. G. of astilbin 2.5 mg/kg or 5 mg/kg significantly ameliorated renal function, reduced kidney index, while it increased body weight and survival time in animals. In addition there was no significant difference in blood glucose level between the STZ-treated group and the astilbin groups. Furthermore, astilbin ameliorated the pathological progress of renal morphology. Astilbin can exert an early renal protective role to DN, inhibit production of TGF-beta1 and especially of CTGF. We suggest that astilbin inhibition of CTGF may be a potential target in DN therapy. This work provides the first evidence for astilbin as a new candidate of DN therapeutic medicine.


Subject(s)
Antioxidants/therapeutic use , Diabetes Mellitus, Experimental/drug therapy , Diabetic Nephropathies/drug therapy , Flavonols/therapeutic use , Kidney/drug effects , Plant Extracts/therapeutic use , Smilax/chemistry , Animals , Antioxidants/pharmacology , Body Weight/drug effects , Cell Line , Connective Tissue Growth Factor/antagonists & inhibitors , Diabetes Mellitus, Experimental/pathology , Diabetes Mellitus, Experimental/physiopathology , Diabetic Nephropathies/pathology , Diabetic Nephropathies/physiopathology , Flavonols/isolation & purification , Flavonols/pharmacology , Glucose/metabolism , Humans , Kidney/pathology , Kidney/physiopathology , Longevity/drug effects , Male , Models, Animal , Phytotherapy , Plant Extracts/chemistry , Plant Extracts/pharmacology , Random Allocation , Rats , Rats, Sprague-Dawley , Rhizome , Transforming Growth Factor beta1/antagonists & inhibitors
8.
Planta Med ; 75(6): 614-9, 2009 May.
Article in English | MEDLINE | ID: mdl-19263342

ABSTRACT

This study was conducted to investigate the efficacy of cornuside, a secoiridoid glucoside compound, in cultured macrophages as well as in an experimental model of sepsis induced by cecal ligation and puncture (CLP) in rats. Cornuside was added to cultured macrophages at different concentrations, and all CLP rats were randomized to receive an intravenous injection of the corresponding drug followed by observation of its antisepsis effect. Our results showed that cornuside downregulated the levels of TNF- alpha, IL-6, and NO production in a dose-dependent manner in activated macrophages, while it upregulated the level of IL-10. Intravenous injection of cornuside or imipenem alone or in combination reduced CLP-induced lethality in rats after CLP. In addition, serum levels of TNF- alpha, IL-6, triggering receptor expressed on myeloid cells, and endotoxin were downregulated. On the other hand, the serum levels of IL-10 were upregulated. Decreased bacterial counts in blood, peritoneum, spleen, liver, and mesenteric lymph nodes and decreased myeloperoxidase in lung, liver, and small intestine also were found after cornuside injection. These data indicate that the antisepsis therapeutic effect of cornuside is mediated by decreased local and systemic levels of a wide spectrum of inflammatory mediators. This work provides first evidence for the clinic use of cornuside as a new immunomodulatory drug that has the capacity to inhibit the inflammatory response in sepsis.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Cornus/chemistry , Glucosides/therapeutic use , Immunologic Factors/therapeutic use , Inflammation Mediators/blood , Plant Extracts/therapeutic use , Pyrans/therapeutic use , Sepsis/drug therapy , Animals , Anti-Bacterial Agents/pharmacology , Colony Count, Microbial , Cytokines/blood , Disease Models, Animal , Dose-Response Relationship, Drug , Down-Regulation , Drug Therapy, Combination , Endotoxins/blood , Fruit , Glucosides/isolation & purification , Glucosides/pharmacology , Imipenem/pharmacology , Imipenem/therapeutic use , Immunologic Factors/pharmacology , Macrophages/drug effects , Male , Myeloid Cells/drug effects , Nitric Oxide/blood , Peroxidase/metabolism , Phytotherapy , Plant Extracts/chemistry , Plant Extracts/pharmacology , Pyrans/isolation & purification , Pyrans/pharmacology , Random Allocation , Rats , Rats, Sprague-Dawley , Sepsis/blood , Up-Regulation
9.
Zhongguo Zhong Yao Za Zhi ; 30(6): 466-8, 2005 Mar.
Article in Chinese | MEDLINE | ID: mdl-15810458

ABSTRACT

OBJECTIVE: To study the protective effect of ligusticum chuanxiong phthalides on cerebral ischemia in rats and its related mechanism of action. METHOD: Middle cerebral artery occlusion (MCAO) model, thrombosis formation, platelet aggregation and hemorrheological parameters were measured to evaluate the protective effect of ligusticum chuanxiong phthalides. RESULT: Ligusticum chuanxiong phthalides could markedly decrease the infarct size and behavior deficits score, inhibit the thrombus formation and platelet aggregation, ameliorate hemorrheological parameters with a dose-dependent manner in rats. CONCLUSION: Ligusticum chuanxiong phthalides has protective effects on focal cerebral ischemia in rats, and its mechanism may be relevant to its inhibition of platelet-dependent thrombosis and amelioration of hemorrheological parameters.


Subject(s)
Benzofurans/pharmacology , Brain Ischemia/pathology , Ligusticum/chemistry , Neuroprotective Agents/pharmacology , Venous Thrombosis/prevention & control , Animals , Benzofurans/isolation & purification , Blood Viscosity/drug effects , Brain Ischemia/blood , Dose-Response Relationship, Drug , Hematocrit , Infarction, Middle Cerebral Artery/blood , Infarction, Middle Cerebral Artery/pathology , Male , Plants, Medicinal/chemistry , Platelet Aggregation/drug effects , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL